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Abstract
Background: Delayed onset muscle soreness (DOMS) is muscle pain and discomfort experienced
approximately one to three days after exercise. DOMS is thought to be a result of microscopic
muscle fiber tears that occur more commonly after eccentric exercise rather than concentric
exercise. This study sought to test the efficacy of a proprietary dietary supplement, BounceBack™,
to alleviate the severity of DOMS after standardized eccentric exercise.
Methods: The study was a randomized, double-blind, placebo-controlled, crossover study. Ten
healthy community-dwelling untrained subjects, ranging in age from 18–45 years, were enrolled.
Mean differences within and between groups were assessed inferentially at each data collection
time-point using t-tests for all outcome measures.
Results: In this controlled pilot study, intake of BounceBack™ capsules for 30 days resulted in a
significant reduction in standardized measures of pain and tenderness post-eccentric exercise
compared to the placebo group. There were trends towards reductions in plasma indicators of
inflammation (high sensitivity C-reactive protein) and muscle damage (creatine phosphokinase and
myoglobin).
Conclusion: BounceBack™ capsules were able to significantly reduce standardized measures of
pain and tenderness at several post-eccentric exercise time points in comparison to placebo. The
differences in the serological markers of DOMS, while not statistically significant, appear to support
the clinical findings. The product appears to have a good safety profile and further study with a
larger sample size is warranted based on the current results.
Background
Delayed onset muscle soreness (DOMS) is muscle pain
and discomfort experienced approximately one to three
days after exercise [1]. DOMS is thought to be a result of
microscopic muscle fiber tears and is more common after
eccentric exercise (the muscle must lengthen or remain
the same length against a weight) rather than concentric
exercise (the muscle can shorten against a weight load).
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While DOMS is not a disease or disorder, it can be painful
and is a concern for athletes because it can limit further
exercise in the days following an initial training [2].
In most cases, DOMS will resolve spontaneously within 3
to 7 days. There is some evidence that ibuprofen,
naproxen, and massage may accelerate the resolution of
DOMS [2]. Treatment strategies have often integrated
multiple therapeutic approaches such as cryotherapy,
ultrasound, compression therapy, stretching and deep tis-
sue massage [3-7]. In addition, several dietary supple-
ments have been tested in the treatment of DOMS
including protein, vitamin C, proteases (enzymes), phos-
phatidylserine, chondroitin sulfate, and fish oil, all with
variable success [2,8-14]. There is no clear consensus in
the extant literature on a method or discipline that can
effectively relieve pain following eccentric exercise.
The test product in this study was BounceBack™ capsules;
a proprietary dietary supplement combination containing
proteolytic enzymes, curcumin, phytosterols from unsa-
ponifiable avocado and soybean oils, vitamin C, and res-
veratrol.
The current study was designed to induce DOMS in
healthy untrained volunteers, assess the level of DOMS
through functional and biochemical methods, and deter-
mine if the BounceBack™ product is superior to placebo in
accelerating recovery from this condition.
Methods
Ethics Approval
Ethics approval was obtained through the Copernicus
Group IRB in Cary, NC prior to the initiation of the study.
Study Sample
Ten healthy community-dwelling untrained subjects were
enrolled. Subjects were between 18 and 45 years of age
(mean 27.73, SD 8.04) and their gender was evenly
divided (5 men, 5 women). As the study followed a cross-
over design, descriptors of the sample are the same,
regardless of whether the subject was in the placebo arm
or the active arm of the study.
Investigational Products
BounceBack™ is a dietary supplement sold in capsule form
by Mannatech, Incorporated (Coppell, TX). The two cap-
sule daily serving contained 258 mg of a proteolytic
enzyme blend that includes bromelain as well as pro-
teases from Aspergillus melleus and A. oryzae. The ingredi-
ents of the two capsules also included 421 mg of tumeric
extract (root/rhizome; standardized to 95% curcumoids),
90 mg of a phytosterol blend (beta-sitosterol, campesterol
and stigmasterol), 20 mg vitamin C and 6 mg Japanese
knotweed extract (root; standardized to 20% resveratrol).
The placebo, which was encapsulated maltodextrin,
looked identical to the test product.
Study Design
The study was a randomized, double-blind, placebo-con-
trolled, crossover study. Mean differences within- and
between-groups were assessed inferentially at each data
collection time-point using t-tests for all outcome meas-
ures. Given the small number of subjects in this pilot
study, the use of an ANOVA or ANCOVA to run repeated
measures was deemed inappropriate.
During the screening visit (Visit 0) subjects were assessed
for eligibility, given a physical exam, randomized into the
test or placebo group, and given the appropriate investiga-
tional product. Subjects received an electronic
SenseWear™ armband (BodyMedia, Pittsburgh, PA) to
record activity data. In order to limit the variable impact
of diet on plasma markers of inflammation, subjects were
given an identical set of frozen foods to consume for each
of the 24-hours periods prior to their day 30 exercise vis-
its.
During each arm of this crossover study, subjects took the
investigational study product for 30 days before returning
for their exercise visit (day 30). After the exercise visit, they
returned on days 31, 32 and 33 for additional assessments
and blood draws. After completing the day 33 visit, sub-
jects underwent a two week washout of the study product
before beginning the second arm of the study, which fol-
lowed the identical timetable.
The eccentric exercise protocol consisted of repeated
quadriceps squats using a Smith Machine: a barbell fixed
within steel rails, so that it can only move vertically. At the
screening visit subjects were asked to complete the maxi-
mum number of squats that they could perform in a five
minute period. This effort was regarded as submaximal
and therefore at the two subsequent exercise visits, sub-
jects were required to perform twice as many squats as
they had performed during the screening visit.
Outcome Measures
The primary outcome measures were assessments of pain
and tenderness. Pain was assessed using a Visual Analog
Scale (VAS) pain score comprised of four subscales (cur-
rent pain, least amount of pain, most amount of pain, and
whether pain was interfering with function) each of which
was measured on a scale from 0 (no pain) to 10 (worst
possible pain). Tenderness was assessed using an algom-
eter (set at level 4) to experimentally induce pain on a pre-
defined point on the patellar tendon five centimeters
above the center of the patella. Subjects then ranked their
pain perception on a scale from 0 to 10. On day 30, assess-
ments were taken at baseline (pre-exercise), and again atJournal of the International Society of Sports Nutrition 2009, 6:14 http://www.jissn.com/content/6/1/14
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six hours post-exercise. Subjects returned for further
assessments 24, 48 and 72 hours post-exercise for of each
arm of the study. Secondary outcomes included assess-
ments of inflammation, muscle damage, flexibility, and
the amount of energy expended prior to exercise.
Blood was drawn on day 30 (pre-exercise), and 6, 24, 48
and 72 hours post exercise. Assays were performed for cre-
atine phosphokinase (CPK), myoglobin, high sensitivity
C-reactive protein (hs-CRP), tumor necrosis factor (TNF)-
alpha, interleukin (IL)-1, and IL-6. Flexibility was meas-
ured using standard flexion and extension measures and
range of motion (ROM) assessments for both legs. Data
on energy expenditure (EE) was collected using the
SenseWear ™ armband device. This armband, which has
been validated by several studies [15-17], uses a 2-axis
accelerometer, a heat flux sensor, a galvanic skin response
sensor, a skin temperature sensor and a near-body ambi-
ent temperature sensor to capture data. These data, in
combination with body weight, height, handedness and
smoking status, are used to calculate EE. The armband was
placed on the upper arm and worn continuously for the
48 hours prior to exercise in order to assess whether the
level of activity prior to exercise impacted any of the pri-
mary or secondary outcomes.
To determine the safety profile of the product compared
with placebo, the following assays were performed on
blood drawn at baseline and again at 72 hours post-exer-
cise in each arm of the study: complete blood count
(CBC), kidney function, liver function, prothrombin
time/partial thromboplastin time (PT/PTT), and urinaly-
sis. Adverse Event monitoring was conducted throughout
the study using standardized assessments at each visit.
Results
Safety Assessment
No adverse events were reported during the study period.
In addition, no clinically significant changes were seen in
any of the laboratory safety values (CBC, liver function,
kidney function, PT/PTT, and urinalysis) in either group.
Pain Assessment
Four different VAS questions were asked regarding pain
perception and a total score was calculated by adding the
scores from the four individual pain questions. The first
three VAS scores were concerned with current pain, least
pain, and worst pain experienced by the subjects. The
fourth question addressed the degree to which pain was
interfering with function. These four questions were asked
at each outcome collection time period. All four scores
were combined to create the VAS sum score.
Subjects taking the test product experienced significant
reductions in overall current pain at six hours (p = 0.039)
and 48 hours (p = 0.001) post exercise. Overall current
pain was not significantly different at any other measure-
ment point. Subjects' taking the test product reported least
pain scores significantly lower than placebo at 6 hours (p
= 0.002) and 48 hours post exercise (p = 0.004). All other
comparison points were not significantly different
between groups for least pain. There was no significant
difference in response to the worst pain question between
groups at any measurement period. The test product
group reported significantly less impact of pain on func-
tion at the pre-exercise evaluation (p = 0.005) and at the
6 hour post-exercise time point (p = 0.047). Differences
between groups were non-significant at all other time
points.
When the VAS scores were summed, the pre-exercise and
48 hours post-exercise totals were significantly lower in
the test product group (p = 0.0001 and p = 0.05, respec-
tively). All other differences for the VAS sum were non-sig-
nificant. (Figure 1)
Tenderness Assessment
The study product group demonstrated significantly less
tenderness at 24 hours after exercise (p = 0.042). No dif-
ferences between groups were seen at any other time
point.
Inflammation Assessment
There were no statistically significant differences between
groups for plasma markers of inflammation (hs-CRP,
TNF-alpha, IL-1, IL-6). The placebo group sustained a
small post-exercise elevation in hs-CRP through the 72
hour visit, while the test product group demonstrated a
trend toward a reduction in hs-CRP during the same time
period (Figure 2).
Pain assessment – visual analogue scale results Figure 1
Pain assessment – visual analogue scale results.Journal of the International Society of Sports Nutrition 2009, 6:14 http://www.jissn.com/content/6/1/14
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Muscle Damage Assessments
Plasma CPK values were not significantly different
between the test product and placebo groups from the
pre-exercise period to 72 hours post exercise. However,
Figure 2 demonstrates that by 24 hours post-exercise, the
placebo group trended toward a higher level of CPK than
the BounceBack™ group. This trend continued through
the 72 hour assessment. A similar phenomenon was
observed for plasma myoglobin, which trended higher at
24 and 72 hours post-exercise in the placebo group. While
not significant, these trends both suggest sustained
increased muscle damage in the placebo group (Figure 3).
Flexion and Extension Measurements
The pre-exercise flexion measurements were equal
between groups for the left leg, but were significantly
greater for the placebo group on the right leg (p = 0.049).
Post-exercise, all flexion measurements were not signifi-
cantly different, with the exception of the 6-hour right leg
flexion measurement which was significantly greater in
the test product group (p = 0.045). When calculating the
difference between pre-exercise and all post-exercise time
point flexion measurements, all values were not signifi-
cantly different between groups with the exception of the
6 hour post-exercise right leg flexion measurement which
was significantly (p = 0.004) in favor of the test product.
Energy Expenditure Data
Data analysis from the SenseWear™ Armband revealed
that there was no significant difference in Total Energy
Expenditure (EE) between the two groups in the 48 hour
period prior to exercise. EE was composed of Measured
Energy Expenditure plus Offbody Energy Expenditure.
The BounceBack™ group demonstrated a greater Measured
Energy Expenditure compared to the placebo group: METs
(physical activity duration and levels) of 720 ± 1012
(mean ± standard deviation) compared to 460 ± 785 (p =
0.009) (Figure 4). In contrast, the Offbody Energy
Expenditure was greater for the placebo group: 661 ± 800
compared to 493 ± 637 (p = 0.009). The BounceBack™
group demonstrated greater Active Energy Expenditure:
METs 211 ± 322 compared to 88 ± 173 for the placebo
group (p = 0.009) (Figure 3). The Average METs was
greater for the BounceBack™ group compared to the pla-
cebo group: 1.9 ± 1.5 compared to 1.3 ± 1.0 (p = 0.013).
Discussion
In this small pilot study, when compared with placebo,
the BounceBack™ product groups experienced significant
reductions in standardized measures of pain and tender-
ness following eccentric exercise. The differences in the
Mean hs-CRP levels Figure 2
Mean hs-CRP levels.
Myoglobin and CPK Figure 3
Myoglobin and CPK.
Energy expenditure 48 hours before exercise protocol Figure 4
Energy expenditure 48 hours before exercise proto-
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serological markers of DOMS, while not statistically sig-
nificant, appear to support the clinical findings. There
were no observed side effects.
BounceBack™ capsules contain proteolytic enzymes, cur-
cumin, phytosterols from unsaponifiable avocado and
soybean oils, vitamin C, and resveratrol: ingredients
intended to provide benefit to individuals pursuing an
active lifestyle. Two previous short-term clinical studies
have examined the effects of ingestion of larger amounts
of proteolytic enzymes on DOMS. A placebo-controlled
study examined the effects of four days of protease supple-
mentation on muscle soreness and contractile perform-
ance after downhill running [11]. One day before exercise
and for three days after exercise, ten male subjects con-
sumed two enzyme tablets (325 mg pancreatic enzymes,
75 mg trypsin, 50 mg papain, 50 mg bromelain, 10 mg
amylase, 10 mg lipase, 10 mg lysozyme, 2 mg chymotryp-
isn) (providing a total of 2.144 g/day proteases, 40 mg/
day amylase and 40 mg/day lipase) or a placebo four
times a day. The treatment group had superior recovery of
contractile function and lower subjective pain ratings
compared to the placebo group.
Another study examined the potential effects of ingestion
of a protease supplement by men for three days on DOMS
created by maximal eccentric isokinetic action of the fore-
arm flexor [10]. The supplement provided 342 mg of Pro-
tease 6.0 and 340 mg Protease 4.5: a total of 682 mg/day
proteases derived from fermentation of Aspergillus oryzae.
In this double-blinded, placebo-controlled, crossover
design study, isometric forearm flexion strength was
greater for the supplement group than for the placebo
group. There was no effect on subjective pain ratings or
blood markers of muscle damage (plasma creatine kinase
activity or myoglobin concentrations).
In addition to protease enzymes, BounceBack™ capsules
contain curcumin. Curcumin has been reported to reduce
pain and swelling associated with inflammation [18]. In a
mouse model, curcumin reduced inflammation and per-
formance deficits in mice that performed eccentric exer-
cise (downhill running) [19]. Other ingredients in
BounceBack™, namely vitamin C and resveratrol, offer
antioxidant support. Antioxidants offer resistance to free
radical proliferation, a theoretical cause of tissue damage
[2]. In addition, BounceBack™ capsules contain phytoster-
ols from unsaponifiable avocado and soybean oils (ASU).
ASU has demonstrated anti-inflammatory activity [20]
and effectiveness in the treatment of osteoarthritis [21].
In the present study BounceBack™ capsules demonstrated
significant improvement in subjective pain and tender-
ness, with no significant improvement in levels of markers
of inflammation, muscle damage or muscle flexion.
BounceBack™ contains a multiple ingredients that are
indicated for relieving the symptoms of DOMS. The
results of this study adds to previous clinical studies con-
ducted on the use of protease supplements for symptoms
of DOM. Compared with those studies [10,11], these
effects were achieved for both men and women following
longer term intake of a smaller amount of protease
enzymes along with supplemental ingredients.
One drawback of this study was the small sample size.
Though the differences in the serological markers for
inflammation and muscle damage were not statistically
significant, a larger sample size may have produced results
in favour of the active product. A subsequent study with a
larger sample based on power calculations from this study
may offer a better idea of the scope of the effectiveness of
BounceBack™ product to mediate muscle damage follow-
ing eccentric exercise.
Conclusion
The BounceBack™ product was able to significantly reduce
standardized measures of pain and tenderness at several
post-eccentric exercise time points, compared to placebo.
The differences in the serological markers of DOMS, while
not statistically significant, appear to support the clinical
findings. The product appears to have a good safety profile
and further study with a larger sample size is warranted
based on the current results.
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